CD4 and HIV-1 infection: For example, ALVAC-specific CD4+ T cells from RV144 vaccinees that show protection against HIV-1 infection display a polarized Th1-like phenotype shown to be less susceptible to HIV-1 infection [88], which could positively influence the efficacy of the RV144 trial.